Equities

Better Therapeutics Inc

BTTX:PKL

Better Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.011
  • Today's Change0.000 / -3.97%
  • Shares traded154.26k
  • 1 Year change-98.43%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024 20:59 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Better Therapeutics, Inc. is a prescription digital therapeutics (PDT) company. The Company is engaged in developing a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases. Its lead PDT product candidate, BT-001, is an investigational prescription digital therapy for the treatment of T2D. The investigational therapy is delivered via software that provides a tailored experience to patients designed to help them address the underlying causes of T2D by making meaningful, sustainable behavioral changes. The BT-001 investigational therapy is rooted in the well-studied, gold standard of behavioral modification therapies, cognitive behavioral therapy (CBT). The Company's platform consists of three behavioral therapy, treatment plans and personalization. Its behavioral therapy consists of lessons, skill- building modules, and a mechanism for goal setting. Its treatment plan is the primary engagement interface for patients.

  • Revenue in USD (TTM)0.00
  • Net income in USD-31.57m
  • Incorporated2020
  • Employees54.00
  • Location
    Better Therapeutics Inc548 Market St. #49404SAN FRANCISCO 94101United StatesUSA
  • Phone+1 (415) 887-2311
  • Fax+1 (302) 655-5049
  • Websitehttps://www.bettertx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Life Stem Genetics Inc0.00-568.02k393.34k1.00--0.21-----0.013-0.0130.000.00760.00----0.00-198.83---330.32--------------0.0241--------------
Himalaya Technologies Inc0.00-629.85k457.44k2.00---------0.003-0.0030.00-0.0020.00-------270.93---------------------------193.23------
Acorda Therapeutics Inc115.66m-263.43m490.63k102.00------0.0042-212.10-212.1093.13-149.560.50681.1412.591,133,961.00-115.42-26.62-266.35-31.9786.3878.22-227.75-111.910.1533-0.69233.57---0.7869-24.24-283.60---62.13--
Meso Numismatics Inc2.44m-10.10m493.51k1.00------0.2022-0.8113-0.81130.1959-1.900.438--33.37---181.33-192.08----69.9760.24-413.98-821.49---0.1106----57.49116.97-76.03--149.35--
Drazcanna Inc2.05m-5.71m501.46k--------0.2449-0.7024-0.70240.24920.10040.685--23.88---191.19---643.20---11.20---279.10-----33.040.2445--------------
NovAccess Global Inc0.00-1.74m535.23k1.00---------0.1193-0.11930.00-0.22460.00----0.00-1,836.30-2,185.89-------------------------177.93------
Hanyuan Biotech International Inc10.65m3.14m539.39k--0.02940.00640.14810.05060.22460.22460.76111.03----------------68.54--29.51--13.3625.660.00--50.51--106.71------
Better Therapeutics Inc0.00-31.57m548.48k54.00---------1.16-1.160.00-0.24490.00----0.00-162.15---378.28-------------15.183.27------1.43------
Molecular Pharmacology (USA) Ltd0.00-105.18k599.73k0.00---------0.0009-0.00090.00-0.01880.00-------976.60-1,219.29------------------------44.29------
Capstone Holding Corp0.00-358.00k646.20k2.00---------6.58-38.120.00-60.700.00-------113.46141.94-199.60173.06-----------2.92--------52.46------
Scisparc Ltd0.00-6.96m658.85k3.00--27.05-----1.22-1.510.000.03440.00----0.00-92.51-69.39-152.41-111.07-------527.17----0.9371--113.73---97.61------
Comera Life Sciences Holdings Inc1.00m-9.35m697.75k12.00------0.6975-0.4901-0.49010.05120.00330.2498--5.0883,367.50-224.98---1,094.30--73.52---900.55------0.00--97.95---237.10------
Data as of May 31 2024. Currency figures normalised to Better Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

0.19%Per cent of shares held by top holders
HolderShares% Held
Capital Investment Advisory Services LLCas of 31 Mar 202471.00k0.13%
XTX Markets LLCas of 31 Mar 202432.67k0.06%
Aspire Private Capital LLCas of 31 Mar 2024200.000.00%
G1 Execution Services LLCas of 31 Mar 20240.000.00%
Geode Capital Management LLCas of 31 Mar 20240.000.00%
BofA Securities, Inc.as of 31 Mar 20240.000.00%
PSI Advisors LLCas of 31 Mar 20240.000.00%
Jane Street Capital LLCas of 31 Mar 20240.000.00%
Corient Private Wealth LLCas of 31 Mar 20240.000.00%
HRT Financial LLCas of 31 Mar 20240.000.00%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.